Nothing Special   »   [go: up one dir, main page]

GB0421288D0 - Pharmaceutical composition containing botulinum neurotoxin - Google Patents

Pharmaceutical composition containing botulinum neurotoxin

Info

Publication number
GB0421288D0
GB0421288D0 GBGB0421288.2A GB0421288A GB0421288D0 GB 0421288 D0 GB0421288 D0 GB 0421288D0 GB 0421288 A GB0421288 A GB 0421288A GB 0421288 D0 GB0421288 D0 GB 0421288D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
composition containing
botulinum neurotoxin
containing botulinum
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0421288.2A
Other versions
GB2418358A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Ltd
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Priority to GB0421288A priority Critical patent/GB2418358A/en
Publication of GB0421288D0 publication Critical patent/GB0421288D0/en
Priority to EP17161071.0A priority patent/EP3210620A1/en
Priority to TR2017/08749T priority patent/TR201708749T4/en
Priority to ES05767945.8T priority patent/ES2526913T3/en
Priority to DK05767871.6T priority patent/DK1776137T3/en
Priority to ES14180875.8T priority patent/ES2627627T3/en
Priority to PL14180875T priority patent/PL2813239T3/en
Priority to PT141808758T priority patent/PT2813239T/en
Priority to EP05767871.6A priority patent/EP1776137B1/en
Priority to PCT/GB2005/003036 priority patent/WO2006013357A1/en
Priority to US11/659,448 priority patent/US20080069841A1/en
Priority to DK14180875.8T priority patent/DK2813239T3/en
Priority to PT57678716T priority patent/PT1776137E/en
Priority to EP14180875.8A priority patent/EP2813239B1/en
Priority to HUE14180875A priority patent/HUE032950T2/en
Priority to ES05767871.6T priority patent/ES2526912T3/en
Priority to PCT/GB2005/003057 priority patent/WO2006013370A1/en
Priority to EP05767945.8A priority patent/EP1778279B1/en
Priority to PL05767871T priority patent/PL1776137T3/en
Priority to US11/659,449 priority patent/US20080102090A1/en
Publication of GB2418358A publication Critical patent/GB2418358A/en
Priority to US12/748,733 priority patent/US20100184689A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • A61K2201/06

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB0421288A 2004-08-04 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin Withdrawn GB2418358A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GB0421288A GB2418358A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin
US11/659,449 US20080102090A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
US11/659,448 US20080069841A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositions Containing Botulinum Neurotoxin A2
PT57678716T PT1776137E (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
ES05767945.8T ES2526913T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin 2
DK05767871.6T DK1776137T3 (en) 2004-08-04 2005-08-03 A pharmaceutical composition comprising botulinum neurotoxin A2
ES14180875.8T ES2627627T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PL14180875T PL2813239T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PT141808758T PT2813239T (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP05767871.6A EP1776137B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
PCT/GB2005/003036 WO2006013357A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP17161071.0A EP3210620A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
DK14180875.8T DK2813239T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
TR2017/08749T TR201708749T4 (en) 2004-08-04 2005-08-03 PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM NEUROTOXIN A2
EP14180875.8A EP2813239B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
HUE14180875A HUE032950T2 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
ES05767871.6T ES2526912T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PCT/GB2005/003057 WO2006013370A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP05767945.8A EP1778279B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
PL05767871T PL1776137T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
US12/748,733 US20100184689A1 (en) 2004-08-04 2010-03-29 Pharmaceutical Composition Containing Botulinum Neurotoxin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0421288A GB2418358A (en) 2004-09-24 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin

Publications (2)

Publication Number Publication Date
GB0421288D0 true GB0421288D0 (en) 2004-10-27
GB2418358A GB2418358A (en) 2006-03-29

Family

ID=33397209

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0421288A Withdrawn GB2418358A (en) 2004-08-04 2004-09-24 Pharmaceutical composition comprising botulinum neurotoxin

Country Status (1)

Country Link
GB (1) GB2418358A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
JP2002501033A (en) * 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Biologically active hemagglutinin of Clostridium botulinum type A and its use
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol

Also Published As

Publication number Publication date
GB2418358A (en) 2006-03-29

Similar Documents

Publication Publication Date Title
IL180380A0 (en) Pharmaceutical composition containing botulinum neurotoxin
IL225848A0 (en) Therapeutic composition with a botulinum neurotoxin
IL177480A0 (en) Pharmaceutical composition
ZA200606154B (en) Pharmaceutical composition comprising pimobendan
EP1871347A4 (en) Pharmaceutical composition
PT2813239T (en) Pharmaceutical composition containing botulinum neurotoxin a2
EP1937255A4 (en) Pharmaceutical composition
EP1862184A4 (en) Pharmaceutical composition
HU0401177D0 (en) Pharmaceutical composition
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
EP1889613A4 (en) Pharmaceutical composition comprising vitamin k
GB2411355B (en) Pharmaceutical composition
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
GB0423950D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0421288D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200701931B (en) Pharmaceutical composition
GB0421290D0 (en) Pharmaceutical composition containing botulinum neurotoxin
HK1216998A1 (en) Pharmaceutical compositions comprising botulinum neurotoxin
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
HUP0500813A2 (en) Pharmaceutical composition containing violaceae extract
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)